← Back to Search

Continuous Glucose Monitoring for High Blood Sugar Risk

N/A

Waitlist Available

Led By Karol Watson, MD, PhD

Research Sponsored by Karol E. Watson, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Overweight and/or obese BMI classification, 25 to 35 kg/m2

History of hypertension, hypertriglyceridemia, heart disease, and/or stroke

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 7 days

Awards & highlights

Study Summary

This trial looks into the relationship between blood sugar, diet, stress and metabolic parameters in people at risk for diabetes. They'll measure and track blood sugar for a week, and record diet and stress.

Who is the study for?

This trial is for adults with a family history of Type 2 diabetes, high blood pressure, heart disease or stroke, overweight/obese BMI (25-35 kg/m2), and slightly elevated blood sugar levels. It's not for tobacco users, heavy alcohol drinkers (>20g/day), those with certain gastrointestinal conditions or surgeries, excessive coffee consumers (>3 cups/day), pregnant/breastfeeding individuals, or people on blood thinners like Warfarin.Check my eligibility

What is being tested?

The study tests how daily stress and diet affect blood sugar in people at risk for diabetes using the Abbott Freestyle Libre 2 glucose monitor. Participants will wear this sensor for a week to track their glucose levels continuously while keeping a food log.See study design

What are the potential side effects?

There are minimal side effects expected from wearing the continuous glucose monitor; however, some may experience skin irritation where the device attaches to the body.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My BMI is between 25 and 35, classifying me as overweight or obese.

Select...

I have a history of high blood pressure, high triglycerides, heart disease, or stroke.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 7 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~7 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Blood glucose time-in-range (TIR)

Trial Design

1Treatment groups

Experimental Treatment

Group I: 7-Day Continuous Glucose Monitoring with Abbott Freestyle Libre 2Experimental Treatment1 Intervention

All participants will go through the same intervention described above.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Karol E. Watson, MDLead Sponsor

University of California, Los AngelesOTHER

1,529 Previous Clinical Trials

10,277,831 Total Patients Enrolled

Karol Watson, MD, PhDPrincipal InvestigatorUniversity of California, Los Angeles

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current opportunities for people to join this trial?

"As detailed on clinicaltrials.gov, this medical trial first posted October 1st 2023 is no longer recruiting patients; however, there are 327 other studies currently active and open for enrolment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Daily Blood Glucose Trends in Patients at Risk for Diabetes

Karol E. Watson, MD 2023. "Daily Blood Glucose Trends in Patients at Risk for Diabetes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06000735.